Shares of Verona Pharma plc (NASDAQ: VRNA) surged by 5.2% on Monday, November 4, 2024, following the company's impressive third-quarter 2024 financial results and updates on the successful launch of its COPD drug Ohtuvayre (ensifentrine).
For the quarter ended September 30, 2024, Verona Pharma reported net sales of $5.6 million, significantly beating analyst estimates of around $2 million. This robust revenue performance was driven by the initial launch of Ohtuvayre, which received FDA approval in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
According to the company, Ohtuvayre recorded over 5,000 prescriptions filled and was prescribed by more than 2,200 unique healthcare professionals across a broad COPD patient population in just the first 12 weeks of launch. Notably, Verona Pharma stated that net sales in October exceeded the third quarter, indicating continued acceleration in demand for the novel COPD therapy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。